BIOHARVEST SCIENCES INC.(BHST)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $25.2M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
BHST Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for BIOHARVEST SCIENCES INC. (BHST), a Healthcare sector company. BHST is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $25.2m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2024), BIOHARVEST SCIENCES INC. reports quarterly revenue of $25.2M, net income of $-12.9M, an operating margin of -27.8%. Top institutional holders of BHST by reported 13-F value include Alyeska Investment Group, L.P., THOMPSON SIEGEL & WALMSLEY, Evercore Wealth Management, based on the most recent SEC filings. BHST trades on the Nasdaq exchange and files with the SEC under CIK 1723464. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BHST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOHARVEST SCIENCES INC. directly from SEC EDGAR.
Revenue
FY 2024
$25.2M
Net Income
FY 2024
$-12.9M
Free Cash Flow
FY 2024
$-9.5M
Operating Margin
FY 2024
-27.8%
D/E Ratio
FY 2024
2.94
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+98.8% YoYNet Income
-2.8% YoYOperating Income
+29.9% YoYTotal Assets
+66.7% YoYTotal Debt
Op. Cash Flow
+21.6% YoYFree Cash Flow
+4.8% YoY| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Revenue | $25.2M +98.8% | $12.7M | — |
| Net Income | $-12.9M -2.8% | $-12.6M | — |
| Operating Income | $-7.0M +29.9% | $-10.0M | — |
| Total Assets | $25.0M +66.7% | $15.0M | — |
| Total Debt | $3.9M | $0.00 | — |
| Operating Cash Flow | $-6.7M +21.6% | $-8.5M | — |
| Free Cash Flow | $-9.5M +4.8% | $-10.0M | — |
Get alerted when BHST's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for BIOHARVEST SCIENCES INC. including:
Top Institutional Holders of BHST
Alyeska Investment Group, L.P.
$1.7M581,441 shTHOMPSON SIEGEL & WALMSLEY LLC
$1.0M364,008 shEvercore Wealth Management, LLC
$618.7K216,343 shTrue North Advisors, LLC
$535.7K187,318 shMagnus Financial Group LLC
$257.4K90,000 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$179.5K63,658 shSilverberg Bernstein Capital Management LLC
$162.8K57,723 shKING LUTHER CAPITAL MANAGEMENT CORP
$114.4K40,000 shTD Waterhouse Canada Inc.
$65.5K23,827 shCITADEL ADVISORS LLC
$58.2K20,652 sh
| Fund | Value | Shares |
|---|---|---|
| Alyeska Investment Group, L.P. | $1.7M | 581,441 |
| THOMPSON SIEGEL & WALMSLEY LLC | $1.0M | 364,008 |
| Evercore Wealth Management, LLC | $618.7K | 216,343 |
| True North Advisors, LLC | $535.7K | 187,318 |
| Magnus Financial Group LLC | $257.4K | 90,000 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $179.5K | 63,658 |
| Silverberg Bernstein Capital Management LLC | $162.8K | 57,723 |
| KING LUTHER CAPITAL MANAGEMENT CORP | $114.4K | 40,000 |
| TD Waterhouse Canada Inc. | $65.5K | 23,827 |
| CITADEL ADVISORS LLC | $58.2K | 20,652 |
More Healthcare Companies
View all Healthcare →Put BHST on your watchlist
Track score changes the day BIOHARVEST SCIENCES INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is BHST a good stock to buy?
13F Pro's AI-powered analysis of BIOHARVEST SCIENCES INC. (BHST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BHST are available on the BHST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BHST is classified as a small company.
Which hedge funds own BHST?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BHST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIOHARVEST SCIENCES INC.'s investment landscape.